The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice

Digestive and Liver Disease

Volumn 40, Issue 10, 2008, Pages 814-820

  Saibeni, S ^a   Virgilio, T ^a   D'Inca R ^b   Spina, L ^c   Bortoli, A ^d   Paccagnella, M ^b   Peli, M ^d   Sablich, R ^e   Meucci, G ^f   Colombo, E ^d   Benedetti, G ^e   Girelli, C M ^g   Casella, G ^h   Grasso, G ⁱ   de Franchis, R ^a   Vecchi, M ^c  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

^d RHO HOSPITAL   (Italy)

^e S Maria Degli Angeli Regional Hospital   (Italy)

^f VALDUCE HOSPITAL   (Italy)

^g BUSTO ARSIZIO HOSPITAL   (Italy)

^h DESIO HOSPITAL   (Italy)

ⁱ Angera Hospital   (Italy)

Author keywords

Inflammatory bowel diseases; Therapy; Thiopurines

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; MERCAPTOPURINE; STEROID;

ABDOMINAL PAIN; ADULT; AGE DISTRIBUTION; ARTHRALGIA; ARTICLE; ASTHENIA; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BONE MARROW TOXICITY; CHICKENPOX; CLINICAL PRACTICE; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; DIARRHEA; DISEASE CLASSIFICATION; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ENTERITIS; FEMALE; FEVER; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEASLES; MELANOMA; MYALGIA; MYCOSIS; NAUSEA; NEOPLASM; OSTEOMYELITIS; PANCREATITIS; RELAPSE; RISK ASSESSMENT; SAMPLING; SEPSIS; SIDE EFFECT; STOMACH ADENOCARCINOMA; TREATMENT DURATION; ULCERATIVE COLITIS; VIRUS INFECTION;

ADULT; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG UTILIZATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 49149112175     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.03.016     Document Type: Article

References (29)

1. Lichtenstein G.R., Abreu M.T., Cohen R., and Tremaine W. American Gastroenterological Association Institute Technical Review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 (2006) 940-987
2. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43 (1992) 329-339
3. Tiede I., Fritz G., Strand S., Poppe D., Dvorsky R., Strand D., et al. CD-28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111 (2003) 1133-1145
4. Dervieux T., Blanco J.G., Krynetski E.Y., Vanin E.F., Roussel M.F., and Relling M.V. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 61 (2001) 5810-5816
5. Crawford D.J., Maddocks J.L., Jones D.N., and Szawlowski P. Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects. J Med Chem 39 (1996) 2690-2695
6. Brooke B.N., Hoffmann D.C., and Swarbrick E.T. Azathioprine for Crohn's disease. Lancet 20 (1969) 612-614
7. Derijks L.J.J., Gilissen L.P.L., Hooymans P.M., and Hommes D.W. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 24 (2006) 715-729
8. Fraser A.G., Orchard T.R., and Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50 (2002) 485-489
9. Gasche C., Scholmerich J., Brynskov J., D'Haens G., Hanauer S.B., Irvine E.J., et al. A simple classification of Crohn's disease: report of the Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 6 (2000) 8-15
10. Munkholm P., Langholz E., Davidsen M., and Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35 (1994) 360-362
11. Louis E., and Belaiche J. Optimizing treatment with thioguanine derivatives in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 17 (2003) 37-46
12. Holtmann M.H., Krummenauer F., Claas C., Kremeyer K., Lorenz D., Rainer O., et al. Long-term effectiveness of azathioprine beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci 51 (2006) 1516-1524
13. George J., Present D.H., Pou R., Bodian C., and Rubin P.H. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 91 (1996) 1711-1714
14. Korelitz B.I., Adler D.J., Mendelsohn R.A., and Sacknoff A.L. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 88 (1993) 1198-1205
15. Glazier K.D., Palance A.L., Griffel L.H., and Das K.M. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol 39 (2005) 21-26
16. Khan Z.H., Mayberry J.F., Spiers N., and Wicks A.C. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion 62 (2000) 249-254
17. Chebli J.M.F., Gaburri P.D., Meirelles de Souza A.F., Pinto A.L., Chebli L.A., Felga G.E., et al. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. J Gastroenterol Hepatol 22 (2007) 268-274
18. Hanauer S.B. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". Rev Gastroenterol Disord 7 Suppl. 2 (2007) S17-S22
19. Warman J.I., Korelitz B.I., Fleisher M.R., and Janardhanam R. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 37 (2003) 220-225
20. De Jong D.J., Goullet M., and Naber T.H.J. Side effects of azathioprine in patients with Crohn's disease. Eur J Gastroenterol Hepatol 16 (2004) 207-212
21. Present D.H., Meltzer S.J., Krumholz M.P., Wolke A., and Korelitz B.I. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 111 (1989) 641-649
22. Connell W.R., Kamm M.A., Ritchie J.K., and Lennard-Jones J.E. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34 (1993) 1081-1085
23. Kirschner B.S. Safety of azathioprine in pediatric patients with inflammatory bowel disease. Gastroenterology 115 (1998) 813-821
24. Pearson D.C., May G.R., Fick G.H., and Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123 (1995) 132-142
25. Korelitz B.I., Zlatanic J., Goel F., and Fuller S. Allergic reactions to 6-mercaptoruine during treatment of inflammatory bowel disease. J Clin Gastroenterol 28 (1999) 341-344
26. Eaden J.A., Abrams K.R., and Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 (2001) 526-535
27. Masunaga Y., Ohno K., Ogawa R., Hashiguchi M., Echizen H., and Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 41 (2007) 21-28
28. Francella A., Dyan A., Bodian C., Rubin P., Chapman M., and Present D.H. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 124 (2003) 9-17
29. Bouhnik Y., Lemann M., Mary J.Y., Scemama G., Taï R., Matuchansky C., et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347 (1996) 215-219